Science Explorer Interactive view Map
Company · Newton · United States

Siamab Therapeutics (United States)

Research works
8
▲ 41% vs 2013–17
Citations
91
11.6 per fractional work
Top-10% rate
100.0%
record average 16.5%
Open access
26%
world 28%

Not ranked overall: Siamab Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does Siamab Therapeutics (United States) publish most on?

By volume in 2022–2025: Cell Adhesion Molecules Research, Glycosylation and Glycoproteins Research and Immunotherapy and Immune Responses.

  1. 1 Cell Adhesion Molecules Research Immunology and Allergy 0 works
  2. 2 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  3. 3 Immunotherapy and Immune Responses Immunology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available25.5%not open74.5%

World: 28% of research is openly available.

with international co-authors6.4%domestic only93.6%

World: 19% is written across borders.

How has Siamab Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 41% higher than in 2013–2017.

grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Newton

All research institutions in Newton

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.